Genzyme's Gaucher disease drug hits main goals in 2 Phase III trials

02/18/2013 | Reuters · Fox Business

Eliglustat tartrate, an experimental drug from Sanofi unit Genzyme, met the primary goals of two late-stage trials involving patients with Gaucher disease. Eliglustat was associated with reductions in spleen size and matched Sanofi's Cerezyme in symptom response. The company plans to use the trials in seeking regulatory approval.

View Full Article in:

Reuters · Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations